查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961056

全球口服蛋白和胜肽市場：市場規模、產業動態、機會分析及預測（2026-2035 年），依產品類型、成分、應用和最終用戶劃分

Global Oral Protein and Peptides Market: By Product Type, By Source, By Application, By End-User - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 280 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球口服蛋白和胜肽市場持續快速成長，預計到 2025 年將達到 95 億美元，並預計在 2035 年實現指數級增長，達到 473.3 億美元。這一令人矚目的成長意味著在 2026 年至 2035 年的預測期內，複合年增長率 (CAGR) 約為 17.42%。這一強勁的成長勢頭表明，口服蛋白和胜肽療法在各個醫療保健領域的重要性日益凸顯，應用也日益廣泛。

2025 年的關鍵發展包括產業領導者雀巢健康科學和達能的策略性產品組合調整。兩家公司都認識到口服蛋白和胜肽作為功能性成分在特定健康益處方面的潛力，並採取重要舉措，以打破食品和製藥行業之間的傳統界限。 兩家公司的投資都集中在酵素水解技術上，該技術可以將長鏈蛋白質分解成具有生物活性的小胜肽。

市場趨勢展望

口服蛋白質和胜肽市場的特點是，成熟的製藥公司積極參與其中，優先研發以開發傳統注射療法的口服替代方案。這些公司意識到對微創治療的需求日益增長，因此正積極投資於創新技術，以提高口服製劑的療效和生物利用度。

2025 年的顯著趨勢包括雀巢健康科學和達能等領先公司進行策略性產品組合調整。兩家公司都採取了果斷措施，整合並模糊食品和製藥行業之間的界限，利用其在營養和健康科學方面的專業知識，開發具有特定治療功效的產品。這些努力的核心是對酶水解技術的大量投資，該技術可以將長鏈蛋白質分解成具有生物活性的小肽。

為了應對供應方面的挑戰，製藥巨頭禮來和諾和諾德已投入大量資金擴大其生產能力。兩家公司宣布計劃在2024年至2025年間投資超過180億美元，用於擴建和升級其位於關鍵地點（包括北卡羅來納州和丹麥）的胜肽合成設施。這些擴建計畫旨在穩定供應鏈，滿足不斷增長的全球需求，並加速先進胜肽療法的研發和生產。

核心成長驅動因子

糖尿病、癌症和胃腸道疾病等慢性病的日益增多是口服蛋白質和胜肽類療法需求的主要驅動因素。這些疾病通常需要長期甚至終身用藥，而傳統上是透過痛苦且不便的每日註射給藥。頻繁注射的負擔不僅影響患者的依從性，還會影響生活質量，因此開發有效的口服替代療法是醫療保健領域的關鍵優先事項。

新機遇

影響口服蛋白質和胜肽市場的一個決定性趨勢是，人們越來越關注 "標靶遞送" 機制。這標誌著人們的關注點從單純關注蛋白質攝取量轉向優先考慮吸收效率和生物利用度。這一轉變反映出人們更深刻地認識到，這些產品的有效性主要取決於蛋白質和胜肽在體內遞送和吸收的效率，而不是攝取的總量。因此，遞送技術的創新已成為該領域產品開發的核心。

優化障礙

由於這些分子的固有特性，特別是其大分子量和高親水性，口服蛋白質和胜肽市場的成長面臨巨大的挑戰。這些特性使得分子難以有效穿過腸道上皮細胞，對吸收進入體循環構成重大障礙。 由於腸壁具有選擇性通透性，較大、吸水性較強的分子難以有效穿過此屏障，導致口服生物利用度有限。

目錄

第一章：摘要整理：口服蛋白質與胜肽市場

第二章：報告概述

  • 研究框架
    • 研究目標
    • 市場定義
    • 市場區隔
  • 研究方法
    • 市場規模估算
    • 質性研究
    • 量化研究
    • 依地區劃分的原始調查受訪者細分
    • 資料三角驗證
    • 研究假設

第三章：口服蛋白質與胜肽市場概述

  • 產業價值鏈分析
    • 原料供應商
    • 研發（研發）
    • 活性藥物成分生產
    • 藥物製劑與給藥技術
    • 合約生產組織 (CMO)
    • 法規與品質管制
    • 行銷與分銷
    • 終端用戶
  • 行業展望
    • 生物製藥產業概覽
    • 口服生物製藥需求不斷成長
    • 醫院引領治療應用，而運動健身產業推動需求成長
    • 給藥技術進步
    • 聚焦生物製藥研發與產品線拓展
    • 不斷發展的監管支持與框架
  • PESTLE 分析
  • 波特五力分析
    • 供應商議價能力
    • 買方議價能力
    • 威脅替代品
    • 新進入者的威脅
    • 競爭強度
  • 市場成長與展望
    • 市場收入估計與預測（2020-2035）
    • 基於推進法的價格分析
  • 市場吸引力分析
    • 基於推進法
  • 實務見解（分析師建議）

第四章 競爭格局概覽

  • 市場集中度
  • 公司佔有率分析（基於價值，2025）
  • 競爭格局分析與標竿分析

第五章：口服蛋白質與胜肽市場分析

第六章：北美口服蛋白質與胜肽市場分析

第七章：歐洲口服蛋白與胜肽市場分析

第八章：亞太地區口服蛋白質和胜肽市場分析

第九章：中東和非洲口服蛋白和胜肽市場分析

第十章：南美洲口服蛋白與胜肽市場分析

第11章 企業簡介

  • AbbVie Inc.
  • Biocon Limited
  • Chiesi Farmaceutici S.p.A.
  • Entera Bio Ltd.
  • Groupe Sanofi
  • Johnson &Johnson Services, Inc.
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Proxima Concepts
  • Synergy Pharma
  • Tarsa Therapeutics, Inc.
  • others

第12章 附錄

簡介目錄
Product Code: AA01261660

The global oral proteins and peptides market is undergoing rapid expansion, with its valuation reaching USD 9.50 billion in 2025 and projected to soar to USD 47.33 billion by 2035. This impressive growth corresponds to a compound annual growth rate (CAGR) of approximately 17.42% during the forecast period from 2026 to 2035. Such a robust trajectory highlights the increasing importance and adoption of oral protein and peptide therapies across various healthcare sectors.

A pivotal development in 2025 was the strategic portfolio restructuring by industry giants Nestle Health Science and Danone. Both companies have taken significant steps to bridge the traditional divide between the food and pharmaceutical sectors, recognizing the potential of oral proteins and peptides as functional ingredients that deliver targeted health benefits. Their investments have heavily focused on enzymatic hydrolysis technologies, which break down long-chain proteins into smaller, bioactive peptides.

Noteworthy Market Developments

The oral protein and peptides market is distinctly marked by the strong involvement of well-established pharmaceutical companies that prioritize research and development focused on creating oral alternatives to traditional injectable therapies. These companies recognize the growing demand for less invasive treatment options and are actively investing in innovative technologies to improve the effectiveness and bioavailability of oral formulations.

A notable development in 2025 was the strategic portfolio restructuring by major players such as Nestle Health Science and Danone. Both companies have taken decisive steps to integrate and blur the lines between the food and pharmaceutical sectors, aiming to leverage their expertise in nutrition and health science to deliver products that offer targeted therapeutic benefits. Central to their approach has been substantial investment in enzymatic hydrolysis technologies, which break down long-chain proteins into smaller, bioactive peptides.

Addressing past supply challenges, pharmaceutical giants Eli Lilly and Novo Nordisk have made significant financial commitments to expand their manufacturing capabilities. Between 2024 and 2025, these companies collectively pledged over $18 billion to upgrade and enlarge peptide synthesis facilities located in key regions like North Carolina and Denmark. This expansion effort aims to stabilize supply chains, meet increasing global demand, and accelerate the development and production of advanced peptide-based therapies.

Core Growth Drivers

The increasing prevalence of chronic diseases such as diabetes, cancer, and gastrointestinal disorders is playing a significant role in driving the demand for oral protein and peptide therapies. These conditions often require long-term, sometimes lifelong, medication regimens, many of which traditionally involve painful and inconvenient daily injections. The burden of frequent injections not only affects patient compliance but also impacts quality of life, making the search for effective oral alternatives a critical priority in healthcare.

Emerging Opportunity Trends

A defining trend shaping the oral protein and peptides market is the growing emphasis on "Targeted Delivery" mechanisms, which mark a significant shift from simply focusing on the quantity of protein consumed to prioritizing the efficiency of absorption and bioavailability. This evolution reflects a deeper understanding that the effectiveness of these products largely depends on how well the proteins and peptides are delivered and absorbed in the body, rather than just the raw amount ingested. As a result, innovation in delivery technologies has become central to product development in this sector.

Barriers to Optimization

The market growth of oral proteins and peptides faces significant challenges due to the inherent characteristics of these molecules, particularly their large molecular size and high hydrophilicity. These properties make it difficult for the molecules to effectively cross the intestinal epithelium, a critical barrier for absorption into the systemic circulation. The intestinal lining is selectively permeable, and larger, water-attracting molecules often struggle to penetrate this barrier efficiently, resulting in limited bioavailability when administered orally.

Detailed Market Segmentation

By Product, nutritional proteins, particularly isolates, hydrolysates, and clinical formulations, dominate the oral protein and peptides market, capturing over 48% of the product share. This leadership stems from their evolution beyond niche bodybuilding supplements to becoming essential components in both clinical nutrition and active lifestyle diets. These protein forms offer superior bioavailability and a rich amino acid profile, making them highly effective for a wide range of health applications. Their versatility allows them to meet the needs of patients requiring medical nutrition support as well as individuals seeking preventative wellness through optimized dietary intake.

By Application, sports and performance nutrition currently dominates the oral protein and peptides market, holding a significant share of 38.56%. This leadership is largely due to a successful rebranding effort that has transformed these products from being perceived solely as fuel for elite athletes to being recognized as essential "active nutrition" for the broader public. The shift reflects a growing awareness among everyday consumers about the benefits of protein and peptide supplementation for general health, fitness, and recovery, rather than just competitive performance. This broader appeal has expanded the market beyond traditional athlete demographics, reaching individuals who pursue an active lifestyle in various forms.

By End User, the "Sports & Fitness Enthusiasts" segment holds the largest share of the oral protein and peptides market, commanding 41.67% of total market revenue. This dominance is closely tied to the unprecedented rise in global participation in physical activity, which has created a substantial and consistently engaged consumer base. As more people around the world commit to active lifestyles, the demand for protein and peptide supplements that support muscle recovery, endurance, and overall performance has surged, driving growth within this particular end-user category.

By Source, despite the increasing attention and discussion around plant-based protein alternatives, animal-derived proteins continue to dominate the oral protein and peptides market. Sources such as whey, casein, and collagen hold the largest market share, accounting for over 34% of the total, largely because of their superior amino acid profiles and higher bioavailability. These characteristics make animal-derived proteins more effective in promoting muscle repair, recovery, and overall health benefits compared to many plant-based options, which often lack one or more essential amino acids or have lower absorption rates.

Segment Breakdown

By Product Type

  • Nutritional Proteins
  • Bioactive Peptides
  • Therapeutic Peptides

By Source

  • Animal-Derived Proteins
  • Plant-Derived Proteins
  • Synthetic/Fermentation-Derived Peptides
  • Collagen-Derived Peptides

By Application

  • Sports & Performance Nutrition
  • Weight Management
  • Immune Health Support
  • Digestive & Gut Health
  • Bone & Joint Health
  • Metabolic Health
  • Therapeutic/Clinical Nutrition
  • Other Functional Applications

By End-User

  • Sports & Fitness Enthusiasts
  • Health & Wellness Consumers
  • Medical & Clinical Nutrition Patients
  • Aging Population / Elderly
  • Lifestyle / Weight Management Users

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Geography Breakdown

  • North America holds a commanding position in the global oral protein and peptides market, accounting for 38.23% of the total market share. This dominant status is the result of strategic and aggressive capital deployment combined with a regulatory environment that is highly supportive of chronic disease management. The region's leadership in this sector is not coincidental but rather the outcome of deliberate structural investments and policies aimed at fostering growth and innovation within the oral protein and peptides industry.
  • A significant factor underpinning North America's dominance is the substantial influx of investment directed toward domestic manufacturing capabilities and clinical validation processes. These investments are designed to ensure that the region remains at the forefront of developing and producing oral peptide products, which are increasingly important for treating a variety of chronic conditions. A notable example of this trend is CordenPharma's decision in July 2024 to invest USD 500 million into its facility in Colorado.

Leading Market Participants

  • AbbVie Inc.
  • Biocon Limited
  • Chiesi Farmaceutici S.p.A.
  • EnteraBio Ltd.
  • Groupe Sanofi
  • Johnson & Johnson Services, Inc.
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Proxima Concepts
  • Synergy Pharma
  • Tarsa Therapeutics, Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Oral Protein and Peptides Market

Chapter 2. Report Description

  • 2.1. Research Framework
    • 2.1.1. Research Objective
    • 2.1.2. Market Definitions
    • 2.1.3. Market Segmentation
  • 2.2. Research Methodology
    • 2.2.1. Market Size Estimation
    • 2.2.2. Qualitative Research
      • 2.2.2.1. Primary & Secondary Sources
    • 2.2.3. Quantitative Research
      • 2.2.3.1. Primary & Secondary Sources
    • 2.2.4. Breakdown of Primary Research Respondents, By Region
    • 2.2.5. Data Triangulation
    • 2.2.6. Assumption for Study

Chapter 3. Oral Protein and Peptides Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Material Suppliers
    • 3.1.2. Research & Development (R&D)
    • 3.1.3. API Manufacturing
    • 3.1.4. Formulation & Drug Delivery Technology
    • 3.1.5. Contract Manufacturing Organizations (CMOs)
    • 3.1.6. Regulatory & Quality Control
    • 3.1.7. Marketing & Distribution
    • 3.1.8. End Users
  • 3.2. Industry Outlook
    • 3.2.1. Biopharmaceutical Industry overview
    • 3.2.2. Rising Demand for Oral Delivery of Biologics
    • 3.2.3. Hospitals Lead Therapeutic Adoption, While Sports & Fitness Segment Drives Volume Demand Stats
    • 3.2.4. Advances in Drug Delivery Technologies
    • 3.2.5. Focus on Biopharmaceutical R&D and Pipeline Expansion
    • 3.2.6. Regulatory Support and Framework Evolutions
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Pricing Analysis, By Propulsion Type
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Propulsion Type
  • 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Oral Protein And Peptides Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases & Increased healthcare spending
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Product Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Nutritional Proteins
        • 5.2.1.1.2. Bioactive Peptides
        • 5.2.1.1.3. Therapeutic Peptides
    • 5.2.2. By Source
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Animal-Derived Proteins
        • 5.2.2.1.2. Plant-Derived Proteins
        • 5.2.2.1.3. Synthetic/Fermentation-Derived Peptides
        • 5.2.2.1.4. Collagen-Derived Peptides
    • 5.2.3. By Application
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Sports & Performance Nutrition
        • 5.2.3.1.2. Weight Management
        • 5.2.3.1.3. Immune Health Support
        • 5.2.3.1.4. Digestive & Gut Health
        • 5.2.3.1.5. Bone & Joint Health
        • 5.2.3.1.6. Metabolic Health
        • 5.2.3.1.7. Therapeutic/Clinical Nutrition
        • 5.2.3.1.8. Other Functional Applications
    • 5.2.4. By End users
      • 5.2.4.1. Sports & Fitness Enthusiasts
      • 5.2.4.2. Health & Wellness Consumers
      • 5.2.4.3. Medical & Clinical Nutrition Patients
      • 5.2.4.4. Aging Population / Elderly
      • 5.2.4.5. Lifestyle / Weight Management Users
    • 5.2.5. By Region
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. North America
          • 5.2.5.1.1.1. The U.S.
          • 5.2.5.1.1.2. Canada
          • 5.2.5.1.1.3. Mexico
        • 5.2.5.1.2. Europe
          • 5.2.5.1.2.1. Western Europe
            • 5.2.5.1.2.1.1. The UK
            • 5.2.5.1.2.1.2. Germany
            • 5.2.5.1.2.1.3. France
            • 5.2.5.1.2.1.4. Italy
            • 5.2.5.1.2.1.5. Spain
            • 5.2.5.1.2.1.6. Rest of Western Europe
          • 5.2.5.1.2.2. Eastern Europe
            • 5.2.5.1.2.2.1. Poland
            • 5.2.5.1.2.2.2. Russia
            • 5.2.5.1.2.2.3. Rest of Eastern Europe
        • 5.2.5.1.3. Asia Pacific
          • 5.2.5.1.3.1. China
          • 5.2.5.1.3.2. India
          • 5.2.5.1.3.3. Japan
          • 5.2.5.1.3.4. South Korea
          • 5.2.5.1.3.5. Australia & New Zealand
          • 5.2.5.1.3.6. ASEAN
            • 5.2.5.1.3.6.1. Indonesia
            • 5.2.5.1.3.6.2. Malaysia
            • 5.2.5.1.3.6.3. Thailand
            • 5.2.5.1.3.6.4. Singapore
            • 5.2.5.1.3.6.5. Rest of ASEAN
          • 5.2.5.1.3.7. Rest of Asia Pacific
        • 5.2.5.1.4. Middle East & Africa
          • 5.2.5.1.4.1. UAE
          • 5.2.5.1.4.2. Saudi Arabia
          • 5.2.5.1.4.3. South Africa
          • 5.2.5.1.4.4. Rest of MEA
        • 5.2.5.1.5. South America
          • 5.2.5.1.5.1. Argentina
          • 5.2.5.1.5.2. Brazil
          • 5.2.5.1.5.3. Rest of South America

Chapter 6. North America Oral Protein And Peptides Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Product Type
    • 6.2.2. By Application Type
    • 6.2.3. By Source
    • 6.2.4. By End users
    • 6.2.5. By Country

Chapter 7. Europe Oral Protein And Peptides Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Product Type
    • 7.2.2. By Application Type
    • 7.2.3. By Source
    • 7.2.4. By End users
    • 7.2.5. By Country

Chapter 8. Asia Pacific Oral Protein And Peptides Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Product Type
    • 8.2.2. By Application Type
    • 8.2.3. By Source
    • 8.2.4. By End users
    • 8.2.5. By Country

Chapter 9. Middle East & Africa Oral Protein And Peptides Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Product Type
    • 9.2.2. By Application Type
    • 9.2.3. By Source
    • 9.2.4. By End users
    • 9.2.5. By Country

Chapter 10. South America Oral Protein And Peptides Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Product Type
    • 10.2.2. By Application Type
    • 10.2.3. By Source
    • 10.2.4. By End users
    • 10.2.5. By Country

Chapter 11. Company Profile (Company Overview, Company Timeline, Organization Structure, Key Product landscape, Financial Matrix, Key Customers/Sectors, Key Competitors, SWOT Analysis, Contact Address, and Business Strategy Outlook)

  • 11.1. AbbVie Inc.
  • 11.2. Biocon Limited
  • 11.3. Chiesi Farmaceutici S.p.A.
  • 11.4. Entera Bio Ltd.
  • 11.5. Groupe Sanofi
  • 11.6. Johnson & Johnson Services, Inc.
  • 11.7. Novo Nordisk A/S
  • 11.8. Oramed Pharmaceuticals Inc.
  • 11.9. Pfizer Inc.
  • 11.10. Proxima Concepts
  • 11.11. Synergy Pharma
  • 11.12. Tarsa Therapeutics, Inc.
  • 11.13. others

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators